부광약품
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
NEWS
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
HOME
CONTACT US
KR
KR
EN
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
JaguAhr
Protekt
NEWS
News
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
NEWS
HOME
NEWS
NEWS
NEWS
ALL
Company news
Product news
R&D news
Company news | Bukwang accelerates globalization together with OCI
-Aiming to become a global pharma through synergy between the two companies-On 2..
2022.02.22
Company news | Bukwang expanded the partnership of ‘Aprovel and CoAprovel’ ..
-Bukwang made a contract with Sanofi-Aventis Korea on sales-marketing expansionB..
2022.01.04
R&D news | Bukwang initiates dosing of SOL-804 in the phase 1 study
- an improved treatment of prostate cancer ,the study will be ended within the f..
2021.12.21
Product news | Bukwang received approval of a new drug ‘Ozanex cream’, a to..
-A short-term topical impetigo treatment from Ferrer Healthcare, Spain-It is a n..
2021.12.15
R&D news | Bukwang registered a composition patent for SOL-804 in the U..
-approved in the U.S.,Europe, Japan, Eurasia, Australia, and MexicoBukwang Pharm..
2021.11.11
R&D news | Approval of phase 1 clinical study for anticancer drug, SOL..
The modified drug for metastatic castration-resistant prostate cancer,expectatio..
2021.10.21
1
2
3
4
5